INFECTION & IMMUNE RESPONSES TO A? HUMAN RETROVIRUS XMRV IN MACAQUES
感染
基本信息
- 批准号:8357452
- 负责人:
- 金额:$ 4.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntiviral AgentsBlood TransfusionChronic PhaseEnsureExhibitsFundingFunding AgencyGammaretrovirusGeneticGrantHealthHumanImmune responseImmunizationInfectionInterferonsKineticsLeadLinkLymphoid TissueMacacaMacaca mulattaModelingNational Center for Research ResourcesOrganPathway interactionsPatientsPrimatesPrincipal InvestigatorProstateProstatic NeoplasmsProtocols documentationReagentResearchResearch InfrastructureResourcesRetroviridaeRoleSafetyScreening procedureSourceTestingUnited States National Institutes of HealthVascular blood supplyViralViremiaViruscostimmune activationin vivo Modelmanprogramsreproductivetooltransmission process
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
The aims of this protocol are to document whether the human XMR virus is able to replicate in a model close to man, i.e. rhesus macaque. If XMRV is able to induce an active infection, what are the viral kinetics, dissemination and antiviral immune responses in this model. A strong correlation has established between the infection with a newly identified gammaretrovirus related to MuLV in prostate tumors from patients exhibiting a genetic inactivation of the RNASEL pathway (R462Q) linked to type I IFN antiviral mechanism. Thus, the hypothesis is that infection with the XMR virus in patients with a deficiency in the RNASEL or potentially other select innate antiviral pathway may lead to or at least contribute to rise of prostate tumors, especially in younger patients. This has obvious health program consequences including the potential for transmission via blood transfusion. This exploratory project will attempt to set up an in vivo model as well as generate reagents for use as screening tools for ensuring the safety of the blood supply. We have shown that XMRV induces a persistent clinically silent infection in rhesus macaques with very low viremia that may be reactivated following immunization/immune activation. Evidence for viral replication was also seen during the chronic phase in most reproductive organs and lymphoid tissues, suggesting likely transmission via sexual contact. This will be tested in new animals thanks to a new source of funding as well as the role of XMRV in the prostate in which early infection appears enriched.
这个子项目是许多利用资源的研究子项目之一
由NIH/NCRR资助的中心拨款提供。子项目的主要支持
而子项目的主要调查员可能是由其他来源提供的,
包括其它NIH来源。 列出的子项目总成本可能
代表子项目使用的中心基础设施的估计数量,
而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。
本方案的目的是记录人类XMR病毒是否能够在接近人类的模型(即恒河猴)中复制。如果XMRV能够诱导活动性感染,那么该模型中的病毒动力学、传播和抗病毒免疫应答是什么?在前列腺肿瘤患者中,与新鉴定的MuLV相关的γ逆转录病毒感染之间存在强相关性,该患者表现出与I型IFN抗病毒机制相关的RNASEL途径(R462 Q)的遗传失活。因此,假设在RNASEL或潜在的其他选择先天性抗病毒途径缺陷的患者中感染XMR病毒可能导致或至少有助于前列腺肿瘤的增加,特别是在年轻患者中。这对健康计划有明显的影响,包括通过输血传播的可能性。该探索性项目将尝试建立体内模型,并生成用作筛选工具的试剂,以确保血液供应的安全性。我们已经表明,XMRV诱导恒河猴持续的临床沉默感染,具有非常低的病毒血症,可能在免疫/免疫激活后重新激活。在慢性期,在大多数生殖器官和淋巴组织中也观察到病毒复制的证据,表明可能通过性接触传播。这将在新的动物中进行测试,这要归功于新的资金来源以及XMRV在前列腺中的作用,其中早期感染似乎有所增加。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Francois J Villinger其他文献
Francois J Villinger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Francois J Villinger', 18)}}的其他基金
Expansion of Macaque Breeding runs at the New Iberia Research Center
新伊比利亚研究中心扩大猕猴繁育规模
- 批准号:
10761902 - 财政年份:2023
- 资助金额:
$ 4.94万 - 项目类别:
“Renovation of Building 29 laboratories at the New Iberia Research Center"
– 翻新新伊比利亚研究中心的 29 栋实验室”
- 批准号:
10547926 - 财政年份:2022
- 资助金额:
$ 4.94万 - 项目类别:
Novel Macaque Breeding Runs at the New Iberia Research Center
新伊比利亚研究中心开展新型猕猴育种工作
- 批准号:
10374603 - 财政年份:2021
- 资助金额:
$ 4.94万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 4.94万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 4.94万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 4.94万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 4.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 4.94万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 4.94万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 4.94万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 4.94万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 4.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 4.94万 - 项目类别: